PROPOFOL
Pharmacodynamics
Baylor College of MedicineSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Pharmacodynamics cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO- Guangzhou General Hospital of Guangzhou Military Command | Phase 4 | BB |
Capivasertib AstraZeneca | Phase 1 | CC |
bb-025 Basking Biosciences, Inc. | Phase 1 | CC |
bb-031 Basking Biosciences, Inc. | Phase 1 | CC |
Same molecule, other indications
PROPOFOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →